Going Public Biotechnology Magazine p.76-77 The new upcoming GCP E6(R2) addendum reforms clinical monitoring and clinical trial management. Risk factors are an important component. What this means for a biotech company: clinical trial risks are easy to foresee, site level risks and operational risks [...]
The pharma world is expecting a new regulatory "earthquake". GCP additions. The upcoming GCP addendum E6 (R2) by many experts is named already as "game changing". Clinical trial design, conducting, oversight, recording and much more is added now to GCP. Let [...]
Join the top RBM community in our newly reworked Webinar with latest RBM insights: How to improve risk awareness and mitigation from clinical study planning How RbM enhances time and financial control What the next upcoming GCP change will bring Read more and [...]
On 24th-25th of September 2015 Artem Andrianov, CEO of Cyntegrity, speaks on 20th DGGF International Meeting in Ulm, Germany. DGGF (German Society for Good Research Practice) is a platform to discuss quality management in pharma world. The CEO of Cyntegrity Artem Andrianov speaks about experience of application of [...]
